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SUMMARY. The production of biopharmaceuticals by transgenic plants is a promising choice to achieve
the multi-kilogram amount of products needed to treat many human diseases. However, this scientific field
is still lacking of approved specific guidelines regarding points to consider for manufacturing and applica-
tion of these products. In such sense, the implementation of new manufacturing processes and quality sys-
tems using the quality risks management is recognized as something of prime importance in the current
pharmaceutical industry. In this work, we summarize the application of the FMEA method to design the
manufacturing process of a plantibody, employed in the hepatitis B vaccine production to ensure the vac-
cine high quality. 
